- Rapport ‘fully prepared’ to launch seizure drug solo, CEO saysIn a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.BioPharma Dive · 1mo ago↗ source
- Summit pulls $500M share sale a day after announcing itThe developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.BioPharma Dive · 1mo ago↗ source
- Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyA strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.